-
University of Texas Helps Launch Project to Correct DMD Using CRISPR/Cas9 Technology
Eric Olson, director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine in Dallas, has teamed up with the nonprofit group CureDuchenne — through its investment arm — to form Exonics Therapeutics.
The new company, based in Cambridge, Massachusetts, will use the CRISPR/Cas9 gene-editing technique known as SingleCut with the aim of correcting up to 80 percent of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD). Click here to learn more about this exciting new research venture.
What are your thoughts on this news?
-
1 Reply
-
I think this technology, and others being used out there such as using a virus to insert the correct genetic material into an individual, all have great potential. We need to find a way to fund and speed research. After all, this technology, if successful and perfected, will help so many rare illnesses. This is the future!
Log in to reply.